An interventional study of molecular analysis in Ovarian Cancer, sponsored by Centre Jean Perrin. Recruiting at 1 site in France. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-20.
Sponsored by Centre Jean Perrin · Not applicable, Interventional, and Other
Among 291 studies in Ovarian Neoplasms with a site in France — 64 open to participants now, 105 under way, 25 of them phase 3. Ovarian Neoplasms · France.
Among the 291 studies in Ovarian Neoplasms with a site in France, this one is the 204th largest by planned enrollment of the 245 interventional ones that give a count, is one of 10 that started in 2026, is one of 53 with no phase, reaches primary completion later than 26 of the 104 other live ones, and was the 283rd registered.
3,381 studies on the registry are indexed under Ovarian Neoplasms; 790 are open to participants now.
Browse Ovarian Neoplasms studies →64 of the 291 studies in Ovarian Neoplasms with a site in France are open now. Recruiting first, the newest first:
Institut Bergonié · Sites in France
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc · Sites in France, United States, Argentina and 19 more countries
Genmab · Sites in France, United States, Belgium and 5 more countries
Gustave Roussy, Cancer Campus, Grand Paris · Sites in France
Boehringer Ingelheim · Sites in France, United States, Belgium and 3 more countries
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 606 Ovarian Neoplasms studies recruiting now, 443 (73%) set no upper age limit and 107 (18%) stop at 75 or younger; 39 take children under 18; 45 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
291 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 64 · Phase 2 92 · Phase 3 65 · Phase 4 2
First in 1995; this study’s year is marked. 10 started in 2026.
This study's planned enrollment of 55 is close to the median of 54 across 2,548 interventional studies indexed under Ovarian Neoplasms.
Median enrollment 205 across the 245 interventional studies, 232 across the 44 observational. Of the 169 that completed or were terminated, 50 (30%) have results posted.
This tab as a report to print or save as PDF → With an account.
143 of 291 have an industry lead sponsor. The 10 most frequent:
Centre Jean Perrin is the lead sponsor of 55 studies on the registry; 8 are open to participants now.
Centre Jean Perrin has 3 studies filed under Ovarian Neoplasms — fewer than ten, so there is no comparison to draw.
31 of the studies in Ovarian Neoplasms with a site in France that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03815643Phase 3EMD Serono Research & Development Institute, Inc.Avelumab Program Rollover Study | 2026-11-24 |
| NCT05059522Phase 3PfizerContinued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing | 2026-12-31 |
| NCT05445778Phase 3AbbVieMirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer | 2027-04 |
| NCT04421963Phase 3AstraZenecaRoll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib | 2027-04-06 |
| NCT06476184Phase 3ARCAGY/ GINECO GROUPUtility of Adjusting Chemotherapy Dose & Dosing Schedule With the SALVage Weekly Dose-dense Regimen in Patients With Poor Prognostic OVARian Cancers Based on the Tumor Unfavorable Primary Chemosensitivity and Incomplete Debulking Surgery | 2027-06 |
Among the 291 studies in Ovarian Neoplasms with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
After having constituted the ORTRAI cohort using the CONSORE database at the Jean PERRIN Center, the objective is to characterize the patients both clinically and biologically, histologically and genomically.
The clinical and biological characterizations will allow us to confirm that our cohort is comparable with data from the literature.
The complement of immunohistochemical and molecular analyses will provide more details on the differences between long-term patients responding to treatment and refractory patients.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Corresponding to one of the two groups below:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
molecular analysis on histological blocks
Genetic: molecular analysis
molecular analysis on histological blocks
Molecular anomalies retained after biological interpretation and allowing the differentiation of refractory patients from long-term responder patients.
Refractory patients are defined as any patient progressing through the first therapeutic line of platinum-based chemotherapy. Long responders are defined as any patient who has not progressed within 5 years of the end of platinum salt treatment.
Time frame: Through study completion, an average of 1 year
Phenotypic criteria differences between refactory patients and long responder patients
Phenotypic criteria will include BMI, personal history and family history
Time frame: Through study completion, an average of 1 year
Clinical criteria differences between refactory patients and long responder patients
Clinical criteria will include age at diagnosis, FIGO stage, initial PCI score, CCO score
Time frame: Through study completion, an average of 1 year
Biological criteria difference between refactory patients and long responder patients
Biological criteria include CA-125
Time frame: Through study completion, an average of 1 year
Histological criteria differences between refactory patient and long responder patients
Histological criteria include histological type, presence of emboli, Ki-67, RO, RP, WT1, PAX8, PD-L1, CD8, p53, HER2
Time frame: Through study completion, an average of 1 year
Plan to share: No
No publications or documents are linked to this record.
Started Jan 2026 (actual). Primary completion is estimated for Dec 2026, 10 months after the start.
Of 282 non-industry interventional studies with no phase under Ovarian Neoplasms, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 76. This study's planned 10 months is below that.
Counting every sponsor, half of 293 studies reached it within 46 months; a quarter within 23 and three quarters within 76.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Centre Jean Perrin